Details:
Insilico Medicine achieves industry first nominating preclinical candidate for idiopathic pulmonary fibrosis with both novel drug target and novel molecule discovered by artificial intelligence.
Lead Product(s): Undisclosed
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2021